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ABSTRACT

The invention provides a method of promoting apoptosis of
human glioblastoma multiforme (GBM) tumor cells. The
method comprises isolating GBM tumor cells from a human
brain biopsy specimen, isolating human neural stem cells
(HNSCs) from the biopsy specimen, transforming the isolated HNSCs with an operative PEX gene, and exposing
GBM tumor cells to the transformed HNSCs to thereby promote apoptosis of the tumor cells mediated by the expressed
PEX gene.
4 Claims, 4 Drawing Sheets
(4 of 4 Drawing Sheet(s) Filed in Color)
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METHOD OF PROMOTING APOPTOSIS OF
GLIOBLASTOMA TUMOR CELLS

SUMMARY OF THE INVENTION

RELATED APPLICATION
5

This application claims priority from provisional application Ser. No. 60/948,277, which was filed on 6 Jul. 2007, and
which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
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The present invention relates to the field of brain cancer
and, more particularly, to a treatment which promotes
destruction of brain tumor cells.
15

BACKGROUND OF THE INVENTION
Patients diagnosed with Glioblastoma multiforme (GBM)
only survive a median time of sixteen (16) months through
extensive neurosurgery and chemotherapy along with radiation therapy. Research has demonstrated that within a timeframe of five (5) days HNSCs are able to migrate next to the
brain tumors in mice. Therefore, it may be concluded that the
tumor itself along with surrounding tissue should contain an
abundant amount of HNSCs. Integrating this knowledge, a
novel GBM therapy may be devised. The long range goal is to
remove tumors from GBM patients, isolate the patient's
Human Neural Stem Cells (HNSCs ), transfect them with the
PEX gene within a mammalian expression vector and then
transplant the patients original HNSCs back into the brain.
PEX is part of the C-terminal fragment of MMP2 metalloproteinase shown to prevent "normal biding to alpha-VI
beta-3 and disrupts angiogenesis and tumor growth". The
central hypothesis is that after transfection of the patients
HNSCs with the PEX gene, the cells will migrate to the site of
tumor cells, express PEX and inhibit tumor growth and possibly promote apoptosis. The objectives ofthis project would
be to achieve the following aims: AIM 1. Optimize a highly
effective method for selecting all three (3) types of cells from
a brain tumor sample. (Cancer Stem Cells, GBM Tumor
Cells, Human Neural Stem Cells) AIM 2. To determine
whether human neural stem cells transfected with the PEX
gene effectively kill the tumor cells in vitro. AIM 3. To investigate whether PEX transfected HNSCs eliminate human
tumor cells in vivo through mouse models. Aim 4. Perform
clinical tests to determine whether PEX transfected HNSCs
eliminate tumor cells in the patient. This proposed research is
innovative, because it focuses on isolating Human Neural
Stem Cells directly from tumor patient samples and transfecting them with an anti-cancerous gene such as PEX. This
research is expected to have the following outcomes: (1)
Isolation of all three types of the cells from patients' brain
tumor samples; (2) demonstration that PEX transfected
HNSCs will effectively inhibit tumor growth in-vitro and
in-vivo; and (3) demonstration of elimination of GBM in
patients using their own HNSCs expressing PEX. This
research is significant because it will provide a novel GBM
therapy using the patient's own HNSCs.
A present challenge in the treatment of glioblastoma multiforme is the fact that patients diagnosed with this disease
rarely undergo surgery which effectively removes all carcinoma cells from the site of the lesion. Therefore a solution to
this problem may be devised through isolation of Human
Neural Stem Cells in the patient's own tumor. Through this
effort we can use the patients HNSCs as therapy for the
patient thus eliminating any possible chance of immunorejection from the patient.
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With the foregoing in mind, the present invention advantageously provides a method of promoting apoptosis in
human glioblastoma multiforme tumor cells (GBMTCs) by
treating them with PEX transformed HNSCs. The present
invention provides one of the initial steps in development of
an effective treatment of GBM through the use of the patient's
own PEX gene transfected HNSCs.
The present invention provides a method of promoting
apoptosis of human glioblastoma multiforme (GBM) tumor
cells. The method comprises isolating
GBM tumor cells from a human brain biopsy specimen and
also isolating human neural stem cells (HNSCs) from the
biopsy specimen. The method then calls for transforming the
isolated HNSCs with a PEX gene. Following transformation,
the method continues by contacting GBM tumor cells (GBMTCs) with the transformed HNSCs to thereby promote
apoptosis of the tumor cells. Those skilled in the art will
recognize that the method may be carried out in vitro, but also
may be carried out in vivo.
BRIEF DESCRIPTION OF THE DRAWINGS
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The application file contains at least one drawing executed
in color. Copies of this patent or patent application publication with color drawing( s) will be provided by the Office upon
request and payment of the necessary fee.
Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 shows phase-contrast photomicrographs of the following: well 1 shows PEX transformed HNSCs cocultured
with GBMTCs and well 4, below, is a control for well 1 with
lipofectamine alone, which causes a slight level of apoptosisf;
well 2 shows another colony of GBMTCs in coculture with
transformed HNSCs, and well 5 shows its lipofectamine control; well 3, shows colony 3 GBMTCs cocultured with transformed HNSCs and well 6 shows its lipofectamine control;
FIG. 2 shows the same wells as shown in FIG. 1, but at a
higher magnification;
FIG. 3 shows GBMTCs in process of apoptosis when cocultured with PEX transformed HNSCs, top left and right
slides and bottom left and right slides are the same pictures at
different magnifications; and
FIG. 4 shows four photomicrographs similar to those of
FIG. 3 but with different GBMTC populations.
DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
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The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the
present specification, including any definitions, will control.

US 8,518,698 Bl

3

4

In addition, the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
The first aim of this experiment was to effectively isolate
all three types of cells: Cancer Stem Cells, Tumor Cells and
Human Neural Stem cells. In order to achieve the following,
surface markers for each cell have been identified: Cancer
Stem Cells: ABCG2, CD133 (Singh, Clarke et al. 2003;
Singh, Hawkins et al. 2004; Mohan, Kandalam et al. 2006;
Park, Selvarajah et al. 2007) Tumor Cells: Tenascin (Brack,
Silacci et al. 2006; Silacci, Brack et al. 2006) Human Neural
Stem Cells: MCM2, 2F7 epitope (Schubert, Coskun et al.
2000; Mohan, Kandalam et al. 2006). Therefore using antibodies for each surface marker, attached to magnetic beads,
selection was carried out using tissue from human brain
biopses. The mixture of cells and antibody was passed
through a magnetic tube and selection for each type of cell
was achieved. After separation, the cells were maintained in
culture in order to determine their morphology so as to provide yet another level to determine correct isolation of each
type of cell. As a method to screen the efficiency of the surface
markers, paraffin embedded tumor tissue was obtained. These
samples were tested against primary antibodies that bind to
these specific surface markers along with secondary antibodies in order to ensure effective binding. Different secondary
antibodies with different fluorescent tags were used to test the
uniqueness of the surface markers proposed. We expected
that this method, when optimized, would be an efficient way
to select and categorize each type of cell from a GBM patient
tumor sample.
After HNSCs wee isolated from patient tumor samples and
maintained in culture for a period of time, they were transfected with the PEX gene according to the procedure shown
below.
The appended figures illustrate apoptosis of the GBMTCs
following coculture with PEX transfected HNSCs.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
Transfection Protocol-For NT2 pcDNA3-PEX
DNA : Lipotectamine
1:2.5
4 ug per DNA Sample
pcDNA3-PEX Colony 1 [0.153 ug/ul]x26.2 ul=4 ug
pcDNA3-PEX Colony 2 [0.175 ug/ul]x22.9 ul=4 ug

pcDNA3-PEX Colony 3 [0.156 ug/ul]x25.7 ul=4 ug
4 ug DNA: 10 ul Lipotectamine/Per Well
6 Well Plate Format:
X-1 X-2 X-3 X-l=Colony 1X-2=Colony2 X-3=Colony 3
X-4 X-5 X-6 Cntrls~X-4=Lipo Alone X-5=lipo Alone
X-6=Lipo Alone
1. Mix DNA with 50 ul ofOpti-MEM:
X-1: (26.2 ul DNA+23.8 ul Opti-MEM) (A-1)
X-2: (22.9 ul DNA+27.1 ul Opti-MEM) (A-2)
X-3: (25.7 ul DNA+24.3 ul Opti-MEM) (A-3)
X-4throughX-6: (50ulofOpti-MEMAlone) (A-4,A-5,
A-6)
2 Mix Lipofectamine before using.
3. Add Lipofeciamine in 50 ul ofOpti-MEM. (10 ul Lipofectamine 40 ul of Opti-MEM) (B-1, B-2, B-3) Also:
(B-4, B-5, B-6)
4. Incubate this solution for 5 minutes at RT. Proceed to
next step within 25 minutes.
5. After 5 minutes mix AB (total volume: 100 ul).
(Al+Bl), (A2+B2), (A3+B3), (A4+B4), (A5+B5),
(A6+B6)
6. Mix this solution gently and incubate for 20 minutes of
RT (solution may appear cloudy)
7. Add the 100 ul DNA, Lipofectamine Complex to the
each well of the 6 well plate with cells and medium and
mix gently by rocking back and forth.
8. Incubate cells at 37° C. for 18-48 hours prior to testing
for transgene expression
9. Medium may be changed after 4-6 hours.
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That which is claimed:
1. A method of promoting apoptosis of human glioblastoma multiforme (GBM) tumor cells, the method comprising:
obtaining a diseased human brain biopsy specimen comprising human GBM tumor cells and normal autologous
human neural stem cells (HNSCs );
isolating the normal autologous HNSCs from the diseased
human brain biopsy specimen from the GBM tumor
cells by use of a specific cell marker;
transforming the isolated normal autologous HNSCs with
an operative PEX gene; and
exposing GBM tumor cells to the transformed normal
autologous HNSCs to thereby promote apoptosis of the
tumor cells mediated by the expressed PEX gene.
2. The method of claim 1 wherein contacting exposing is
effected in vitro.
3. The method of claim 1 wherein contacting exposing is
effected in vivo.
4. A method of producing transformed human neural stem
cells (NHSCs ), the method comprising:
obtaining a diseased human brain biopsy specimen comprising human GBM tumor cells and normal autologous
human neural stem cells (HNSCs );
isolating the normal autologous HNSCs from the diseased
human brain biopsy specimen from the GBM tumor
cells by use of a specific cell marker; and
transforming the isolated normal autologous HNSCs with
an operative PEX gene.
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